Article Details
Retrieved on: 2025-04-25 15:03:03
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses the FDA's plan to phase out animal testing, particularly for monoclonal antibodies, in favor of New Approach Methodologies (NAMs) due to ethical concerns and poor predictive success for diseases like Alzheimer’s. This aligns with the tags by highlighting shifts in drug development, biotechnology, and regulatory practices.
Article found on: www.morganlewis.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here